Neuren Pharmaceuticals Limited (ASX:NEU)
Australia · Delayed Price · Currency is AUD 20.54
+0.18 (0.88%)
Sep 17, 2026, 4:17 PM AEST
Neuren Pharmaceuticals Ratios and Metrics
Market cap in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,581 | 2,357 | 1,588 | 3,178 | 1,001 | 475 | |
Market Cap Growth | 4.28% | 48.44% | -50.04% | 217.33% | 110.87% | 222.46% |
Enterprise Value | 2,295 | 2,057 | 1,374 | 3,092 | 970 | 457 |
Last Close Price | 20.36 | 18.47 | 12.41 | 24.79 | 7.89 | 3.74 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 130.58 | 77.43 | 11.18 | 20.23 | 5442.54 | - |
Forward PE | 40.64 | 55.42 | 19.45 | 32.20 | 19.55 | 135.13 |
PS Ratio | 37.12 | 36.46 | 7.32 | 13.70 | 64.96 | 148.54 |
PB Ratio | 7.74 | 6.96 | 4.36 | 15.49 | 24.08 | 12.10 |
P/TBV Ratio | 7.74 | 6.96 | 4.36 | 15.49 | 24.08 | 12.10 |
P/FCF Ratio | 508.39 | 18.80 | - | 17.19 | 279.73 | - |
P/OCF Ratio | 504.42 | 18.79 | - | 17.18 | 278.25 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 33.00 | 31.82 | 6.34 | 13.33 | 62.94 | 142.84 |
EV/EBITDA Ratio | 165.22 | 93.25 | 7.67 | 15.52 | - | - |
EV/EBIT Ratio | 165.53 | 93.35 | 7.67 | 15.52 | - | - |
EV/FCF Ratio | 451.96 | 16.41 | - | 16.73 | 271.04 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Debt / Equity Ratio | -0.86 | -0.87 | -0.61 | -1.11 | -0.97 | -0.94 |
Net Debt / EBITDA Ratio | -20.63 | -13.42 | -1.24 | -1.15 | 55.65 | 4.47 |
Net Debt / FCF Ratio | -56.44 | -2.36 | 19.70 | -1.24 | -11.22 | 3.69 |
Asset Turnover | 0.21 | 0.17 | 0.66 | 1.59 | 0.37 | 0.10 |
Quick Ratio | 44.56 | 74.40 | 8.69 | 5.68 | 24.59 | 47.58 |
Current Ratio | 46.46 | 76.60 | 8.73 | 5.78 | 25.77 | 49.87 |
Return on Equity (ROE) | 6.17% | 8.67% | 49.92% | 127.30% | 0.46% | -24.57% |
Return on Assets (ROA) | 2.58% | 3.66% | 34.05% | 85.52% | -1.10% | -15.83% |
Return on Invested Capital (ROIC) | 22.36% | 18.73% | 235.12% | - | -37.74% | -663.42% |
Return on Capital Employed (ROCE) | 4.20% | 6.50% | 49.20% | 97.10% | -1.80% | -21.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.78% | 1.29% | 8.95% | 4.94% | 0.02% | -1.64% |
FCF Yield | 0.20% | 5.32% | -0.71% | 5.82% | 0.36% | -2.10% |
Buyback Yield / Dilution | - | 0.01% | -0.01% | -1.44% | -8.76% | -10.71% |